Oh no. I think I 'm headed for melanoma. At the very least, I seem to have a very high risk for developing the disease, thanks to my once-stubborn pursuit of a silly tan.

Think about this:

A review of seven different studies concludes that using a tanning bed under the age of 35 -- I'm so guilty -- can increase the risk of melanoma by 75 percent. Even those who have ever used indoor tanning were 15 percent more likely to develop the disease.

We're talking the deadliest form of skin cancer here. So deadly some experts are recommending strong measures to restrict the use of tanning beds by young people. Adults should be discouraged from tanning, some say, but access should be limited for those under the age of 18.

New Jersey already has regulations in place -- those under 14 are banned from tanning salons and anyone between 14 and 18 must have parental consent.

If I could turn back time, I would listen to my grandma. She told me the sun -- and tanning beds too -- were no good. But I was young. And I didn't care.

Now I'm older. And I care. But it may be too late. It seems this could be one lesson I learn the hard way.

Increased intake of vitamin C from the diet, but not from supplements may slash the risk of mouth cancer by 48 percent, says an epidemiological study.

The study, published in the International Journal of Cancer, used data on supplement use and diet for 42,340 men in the Health Professional Follow-Up Study. During the course of the study, 207 oral pre-malignant lesions were documented.

Vitamin C from dietary sources was significantly associated with a reduced risk of mouth cancer, but no association with the vitamin from supplements was found.

Vitamin C is needed to form collagen, a tissue that helps to hold cells together. It's essential for healthy bones, teeth, gums, and blood vessels. It helps the body absorb iron and calcium, aids in wound healing and contributes to brain function.

You can find high levels of vitamin C in red berries, kiwi, red and green bell peppers, tomatoes, broccoli, spinach, and juices made from guava, grapefruit and orange.

Skin cancer awareness month doesn't arrive until May, but Olay and the American Society for Dermatologic Surgery have already chosen their spokesperson for the 2007 Skin Cancer Takes Friends campaign.

Emmy-nominated Desperate Housewives actress Marcia Cross will kick off a nationwide free skin cancer screening and education initiative to alert Americans about the importance of early detection and prevention in the fight against a disease that has affected her personally.

"I'm proud to be part of a cause that is near and dear to my heart," says Cross. "Having had two family members suffer from melanoma, I've come to understand the importance of skin cancer detection and prevention. Knowing what I know about the dangers of sun exposure, I take extra care to protect myself with a large hat, sunglasses, daily UV protection, and of course, an annual screening."

Cross has become an partner in the crusade against skin cancer so she can encourage people to protect not only themselves but their family members and friends too.

Beginning on April 1, log onto skincancertakesfriends.org to find a dermatologist offering free screenings in your area. Take a friend with you to your screening during the months of May, June, and July and each of you will pay not a penny.

Many people don't know just how dangerous skin cancer can be. Yet it's the most common form of cancer in the United States and the incidence of melanoma -- the deadliest form of the disease -- is rising faster than any other cancer. Right now, one in five Americans will develop skin cancer during their lifetimes. And every 67 minutes, someone dies of melanoma.

Screening is a must for everyone -- regardless of skin color, ethnicity, age, or geography. So mark your calendar for April 1 if you'd like a free screening. If money is not an issue, make an appointment today.

Breast cancer drug tamoxifen, designed to cut recurrence in women with estrogen-receptor positive disease, has been shown to continue working long after women stop taking the drug. And two studies suggest it might also offer long-term protection for healthy women with high risk of developing breast cancer.

One such study found the drug decreases risk of hormone-sensitive breast cancer by 39 percent over 20 years. Another shows a 34 percent decrease for up to eight years after the therapy concludes.

Published in the Journal of the National Cancer Institute, one study -- the International Breast Cancer Intervention Study, or IBIS -- looked at 7,145 women at high risk of breast cancer. And for the first time, clear evidence has surfaced in support of the merits of tamoxifen after the completion of treatment.

IBIS study participants took either a daily dose of tamoxifen or a placebo for five years. At the eight-year mark, 87 women who took the actual drug were diagnosed with estrogen-receptor positive breast cancer. And 129 women in the placebo group were diagnosed with the same disease.

In the second study, researchers from the Royal Marsden Hospital in London investigated 20-year data on 2,471 healthy women at high risk of breast cancer who took tamoxifen for six or seven years. Similar results were found.

Despite the benefits of tamoxifen as a preventative treatment, the drug is not currently approved for this use in the UK, where breast cancer is the most common form of female cancer.

A decade of research specific to the inherited form of pancreatic cancer has turned up a gene that could lead to earlier diagnosis and treatment for one of the deadliest forms of cancer.

The magical gene -- called palladin -- was discovered at the University of Washington after the extensive study of one family that has lost nine members over four generations to pancreatic cancer and has nine additional members with early signs of the disease.

Washington resident Ryan Chappell, a member of this family who had his pancreas removed just before cancer could strike, is very excited about this breakthrough.

"I feel really good that my family has not suffered (in vain)," the 21-year-old says. "Something has been accomplished from their contribution."

What the Chappell family has contributed to research is an understanding of a breakdown in a gene that makes a protein for the skeleton of pancreas cells. In this one family, the gene was mutated and produced large amounts of a misshapen protein that rolls like tumbleweed through the body, migrating 50 percent faster than other cells.

Scientists hope to translate their research findings into a diagnostic test to find excess amounts of the protein and to prevent the cancer cells from moving.

For now, early detection of pancreatic cancer rare because the pancreas is deep in the body, making it difficult to feel or see tumors through imaging tests. Symptoms -- like jaundice, abdominal and back pain, and digestive problems -- usually surface only after the cancer has spread.

Cancer of the pancreas is rare but is the third-leading cause of cancer death among people age 40 to 60.

In a Phase III trial involving 878 lung cancer patients, the drug bevacizumab, known as Avastin, increased the overall survival rate to 35 percent when combined with the chemotherapy drugs paclitaxel and carboplatin. Patients who were given paclitaxel and carboplatin without Avastin had a 15 percent chance of responding to treatment.

Two months ago, the Food and Drug Administration approved Avastin as a first-line treatment for patients with inoperable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer. Avastin works by stopping the formation of blood vessels that feed oxygen and nutrients needed for tumor growth. Because the drug is a targeted therapy, in that it leaves healthy tissue alone while going after cancer cells, some of the traditional side-effects from conventional chemotherapy, such as hair loss, nausea, or vomiting, are avoided.

According to Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Chief of Hematology/Oncology's Dr. Joan Schiller, "Twenty years ago, we thought no treatment could help patients with advanced lung cancer. Ten years ago, we found that chemotherapy could improve survival of these patients. Now, we are finding out that this very unique drug called Avastin can also help improve survival even more. Avastin is the first of this very exciting family of drugs to be approved for lung cancer, and there are several other drugs of this type under development which may prove to work even better."

Photographer Sharon Seligman's images are inspired by her personal journeys. She photographs people and birds and residential communities. She also captures the journeys of women enduring breast cancer. Her work speaks of the human experience. It speaks of her own experience. It speaks volumes.

Bearing Witness: Beyond the Surface of Breast Cancer is one of Seligman's portfolios. It's a photographic trip down memory lane, depicting self-portraits of courageous breast cancer survivors. Seligman tells her own story in words that border the left side of each portrait. Captions to the right of each black and white photograph offer a glimpse into the life of each woman whose being is displayed in raw form, for all to see, for all to contemplate, for all to appreciate.

And then in another portfolio, Seligman offers more photographs, more visions of the breast cancer experience.

Seligman aims to share the physical changes that come from breast cancer, to project the inner truths. Clearly, she is right on target.

In the not-too-distant future, dermatologists will be able to diagnose skin cancer without ever cutting the skin.

Right now, doctors cut out all suspicious lesions in order to examine them, to determine if they are cancerous or not. But with the development of a new microscope, cells can be examined right on the body -- without cutting.

Moles matter, reported Matt Lauer on Thursday's TODAY show during an interview with a skin cancer expert. Moles are highly associated with melanoma, the deadliest form of skin cancer. So it is critical that each mole is investigated. With this new high resolution technology -- essentially a video biopsy -- a camera will allow doctors to view cells, zero in on the area of concern, and pinpoint the exact cells that make up a mole. If the cells are similar in shape and size and have equal distribution, the mole is normal. If the individual cells are irregular and have no uniform pattern, the mole is abnormal and probably cancerous.

While cutting for biopsy purposes will one day be a thing of the past, cutting will still be necessary if a mole is characterized by cancerous cells. If it's cancer, it must come out. But the video biopsy can be used to map the border and boundaries and will allow for precise removal of the mole.

This technology is still developing -- but one day, perhaps eight to 10 years from now -- doctors will be able to more consistently detect cancer without removal of skin. For now, they must take a piece of the mole and put it under a microscope.

There are definite warning signs of skin cancer. Any mole that is asymmetrical with irregular borders and varied, dark colors should be reported to a physician. Also, any mole that changes in color, shape, or size and is bigger than a pencil eraser is cause for concern.

George W. Bush declared five years ago that no federal funding would be allocated for embryonic stem cell research. He has not changed his mind -- and two weeks ago vetoed a bill that would allow this research. He says that supporting the bill would be supporting the taking of innocent human life in order to find medical benefits for others. For Bush, it crosses a moral boundary. But most Americans support stem cell research and would like to see the Bush White House loosen its restrictions, says Kathy Hudson, director of the Genetics and Public Policy Center at Johns Hopkins University in Washington. Until this happens, though, scientists and researchers find themselves in an ethically-charged minefield, operating carefully and responsibly and ethically.

Dr. Peter Dirks -- a neurosurgeon specializing in childhood brain cancer at Toronto's Hospital for Sick Children who has been making headlines around the world for isolating brain cancer stem cells two years ago -- is one person weighing in on controversial issue of stem cell research. Dirks does not use embryonic stem cells but instead uses cells from tumors removed during brain surgery that would otherwise be discarded. But he says embryonic stem cell research is critical for his success. It's what has led to the findings that exist today -- and it holds the clues for further discovery. It's a delicate matter, though, regardless of the politics surrounding the issue. Before he harvests stem cells from any patient's brain tumor, for example, Dirks asks parents to sign a three and a half-page consent form. And that's just the beginning.

Federally-funded embryonic stem cell research does not yet have its beginning here in the United States. Maybe the tides will change. Maybe we will see progress. Maybe we won't. Only time will tell.

Herceptin -- a targeted breast cancer drug used to treat women who are Her2 positive -- has received rave reviews and has shown great promise in cutting down on recurrence of this aggressive form of breast cancer. Given over the course of 52 weeks, Herceptin is wondrous for its lack of short-term side effects. There is no hair loss, no compromise of blood counts, no significant sickness. For me, fatigue may have resulted from this treatment -- but it's unclear to me really whether it was the Herceptin or the two small boys I have living in my house that most contributed to my occasional exhaustion. Regardless, I functioned well while receiving Herceptin for the past year -- and I did not suffer anything more than a twinge of pain when my port was accessed for each treatment. In the short term, I have fared well. In the long term, the jury is still out.